Review
Immune modification therapy for myasthenia gravis
Ning Zhang, Ni Tang, Xiaoyan Zhang, Rong Yin
Published 2020-01-05
Cite as Int J Immunol, 2020, 43(1): 98-102. DOI: 10.3760/cma.j.issn.1673-4394.2020.01.019
Abstract
Myasthenia gravis is an autoimmune disease that is primarily mediated by acetylcholine receptor antibodies involving the neuromuscular junction.Immunomodification therapy can significantly reduce the mortality and improve the quality of social life of myasthenia gravis patients, but there are many kinds of immunosuppressants and dose-related adverse reactions.And so far, there is no definite conclusion on the selection and the specific use of immunosuppressants.This review summarized the clinical application of immunotherapy in myasthenia gravis, so as to provide a reference for clinicians in the treatment of myasthenia gravis.
Key words:
Myasthenia gravis; Immunomodified therapy; Immunosuppressive agents; Side effects
Contributor Information
Ning Zhang
Department of Neurology, Clinical Medical College, Gansu University of Traditional Chinese Medicine, Lanzhou 730000, China
Ni Tang
Department of Neurology, Clinical Medical College, Gansu University of Traditional Chinese Medicine, Lanzhou 730000, China
Xiaoyan Zhang
Chinese People's Liberation Army Joint Service Support Force 940 Hospital Department of Neurology, Lanzhou 730050, China
Rong Yin
Chinese People's Liberation Army Joint Service Support Force 940 Hospital Department of Neurology, Lanzhou 730050, China